S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
66,000% upside on tiny biotech? (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
66,000% upside on tiny biotech? (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
66,000% upside on tiny biotech? (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
66,000% upside on tiny biotech? (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
OTCMKTS:ABCZY

Abcam (ABCZY) Stock Forecast, Price & News

Compare
Today's Range
N/A
50-Day Range
$19.40
$19.40
52-Week Range
N/A
Volume
5,400 shs
Average Volume
4,712 shs
Market Capitalization
$3.98 billion
P/E Ratio
N/A
Dividend Yield
0.36%
Price Target
N/A

ABCZY stock logo

About Abcam (OTCMKTS:ABCZY) Stock

Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Germany, the United Kingdom, and internationally. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. The company also offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc has partnership with Cancer Research UK for the development and commercialization of novel custom antibodies to support the acceleration of cancer research. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.


ABCZY Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Abcam plc Statement on Dr. Jonathan Milner’s Announcement
Abcam founder Jonathan Milner renews clear-out bid
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Abcam founder Jonathan Milner opposes Danaher deal
Abcam founder calls on board to justify takeover bid
Abcam agrees $5.7bn US takeover deal
Danaher to Acquire Abcam
Danaher to acquire Abcam for $5.7 billion
Danaher to acquire Abcam for $24.00 per Share
Expert Ratings for Abcam
Abcam plc: All Resolutions Withdrawn at Abcam's EGM
See More Headlines
Receive ABCZY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abcam and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Industrial Inorganic Chemicals
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ABCZY
Previous Symbol
NASDAQ:ABCZY
CIK
N/A
Fax
N/A
Employees
1,492
Year Founded
1998

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$336.37 million

Miscellaneous

Free Float
N/A
Market Cap
$3.98 billion
Optionable
Not Optionable
Beta
1.29

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Alan Thomas Hirzel BS (Age 52)
    MS, MBA, CEO & Exec. Director
  • Mr. Michael Shaun Baldock (Age 54)
    CFO & Director
  • Dr. Jonathan Simon Milner (Age 55)
    Co-Founder & Non-Exec. Deputy Chairman
  • Mr. Mark Dermody
    Interim CIO
  • James Staveley
    VP of Investor Relations













ABCZY Stock - Frequently Asked Questions

Is Abcam a good dividend stock?

Abcam (OTCMKTS:ABCZY) pays an annual dividend of $0.07 per share and currently has a dividend yield of 0.36%.
Read our dividend analysis for ABCZY.

What is Abcam's stock symbol?

Abcam trades on the OTCMKTS under the ticker symbol "ABCZY."

How do I buy shares of Abcam?

Shares of ABCZY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How much money does Abcam make?

Abcam (OTCMKTS:ABCZY) has a market capitalization of $0.00 and generates $336.37 million in revenue each year.

How many employees does Abcam have?

The company employs 1,492 workers across the globe.

Does Abcam have any subsidiaries?
The following companies are subsidiares of Abcam: Abcam (US) Ltd., Abcam Trading (Shanghai) Co. Ltd., Abcam US Group Holdings Inc., and Epitomics Inc.
Read More
How can I contact Abcam?

The official website for the company is www.abcam.com. The company can be reached via phone at 44 1223 696 000.

This page (OTCMKTS:ABCZY) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -